Peter C. Adamson named global development therapeutic area head of oncology and pediatric innovation at Sanofi

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Peter Adamson

Peter C. Adamson was named global development therapeutic area head of oncology and pediatric innovation at Sanofi. Based in Cambridge, MA, Adamson will lead the global development in cancer, and will work with leaders across therapeutic areas to further pediatric drug development efforts.

Adamson joins Sanofi from the Perelman School of Medicine of the University of Pennsylvania, where he was professor of pediatrics and pharmacology, and held the Alan R. Cohen Endowed Chair in Pediatrics at Children’s Hospital of Philadelphia. For almost 10 years prior to joining Sanofi, Adamson chaired the Children’s Oncology Group, an NCI-supported international consortium of more than 220 centers that conduct clinical-translational research, including large-scale clinical trials, in children and adolescents with cancer.

Adamson is board certified in hematology/oncology and clinical pharmacology. He was appointed by President Obama to the National Cancer Advisory Board, where he continues to serve. Adamson also served on the blue-ribbon panel for the Beau Biden National Cancer Moonshot Initiative.

Table of Contents

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login